Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTS,S/AS01E vaccine and perennial malaria chemoprevention in Ghanaian children
PACTR202307828402450Phase 3Not yet recruiting
- Sponsor
- PATH
- Start
- Aug 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of plasmodium falciparum and hepatitis b vaccine (recombinant, adjuvanted), sulfadoxine, pyrimethamine and amodiaquine in malaria (3 arms), sponsored by PATH. Primary endpoint: Incidence of clinical malaria. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
plasmodium falciparum and hepatitis b vaccine (recombinant, adjuvanted)sulfadoxinepyrimethamineamodiaquine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202307828402450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202307828402450.